Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

Absztrakt
Leírás
Kulcsszavak
Forrás
HemaSphere. -6 : 12 (2022), p. 1-10. -Hemasphere. - 2572-9241